Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

Prurigo Nodularis Companies are Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Prurigo Nodularis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been ...

The FDA has granted nemolizumab Priority Review for the treatment of prurigo nodularis. The Food and Drug Administration (FDA) has accepted for review the Biologics License Applications (BLA) for ...

Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life disruptions, affects approximately 75,000 adults in the United States, who are most in need of ...

Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...

Pune, Maharashtra, India, January 19 2021 (Wiredrelease) Prudour Pvt. Ltd –:Market.us, one of the worlds leading by prominent market research firms has released a new recent work on “Prurigo Nodularis ...

The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...